Brokerages Anticipate AnaptysBio Inc (ANAB) to Post -$0.69 EPS

Wall Street brokerages expect AnaptysBio Inc (NASDAQ:ANAB) to announce ($0.69) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for AnaptysBio’s earnings. The highest EPS estimate is ($0.66) and the lowest is ($0.72). AnaptysBio posted earnings of ($0.45) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 53.3%. The company is scheduled to report its next quarterly earnings results on Tuesday, November 6th.

Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for AnaptysBio.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.70) by $0.13.

ANAB has been the subject of a number of recent analyst reports. Cantor Fitzgerald set a $124.00 price target on shares of AnaptysBio and gave the stock a “buy” rating in a report on Saturday, September 22nd. Zacks Investment Research downgraded shares of AnaptysBio from a “buy” rating to a “hold” rating in a report on Tuesday, October 9th. Stifel Nicolaus set a $127.00 price target on shares of AnaptysBio and gave the stock a “buy” rating in a report on Friday, September 14th. JMP Securities cut their price target on shares of AnaptysBio from $180.00 to $153.00 and set a “buy” rating for the company in a report on Wednesday, August 15th. Finally, Credit Suisse Group initiated coverage on shares of AnaptysBio in a research note on Thursday, July 19th. They issued an “outperform” rating and a $104.00 price objective for the company. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. AnaptysBio presently has a consensus rating of “Buy” and a consensus target price of $130.90.

Shares of AnaptysBio stock opened at $81.24 on Friday. AnaptysBio has a 1-year low of $60.42 and a 1-year high of $134.00. The company has a quick ratio of 16.19, a current ratio of 16.19 and a debt-to-equity ratio of 0.01. The company has a market cap of $2.40 billion, a PE ratio of -49.56 and a beta of 2.77.

A number of large investors have recently modified their holdings of ANAB. Wells Fargo & Company MN lifted its stake in AnaptysBio by 53.8% in the 1st quarter. Wells Fargo & Company MN now owns 36,294 shares of the biotechnology company’s stock valued at $3,777,000 after purchasing an additional 12,701 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its stake in AnaptysBio by 5.8% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 79,275 shares of the biotechnology company’s stock valued at $8,251,000 after purchasing an additional 4,335 shares during the last quarter. Northern Trust Corp lifted its stake in AnaptysBio by 4.3% in the 1st quarter. Northern Trust Corp now owns 197,970 shares of the biotechnology company’s stock valued at $20,605,000 after purchasing an additional 8,164 shares during the last quarter. BlackRock Inc. lifted its stake in AnaptysBio by 2.1% in the 1st quarter. BlackRock Inc. now owns 1,423,117 shares of the biotechnology company’s stock valued at $148,119,000 after purchasing an additional 29,812 shares during the last quarter. Finally, New York State Common Retirement Fund lifted its stake in AnaptysBio by 56.2% in the 1st quarter. New York State Common Retirement Fund now owns 21,839 shares of the biotechnology company’s stock valued at $2,273,000 after purchasing an additional 7,855 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.

See Also: What are the reasons investors use put options?

Get a free copy of the Zacks research report on AnaptysBio (ANAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply